Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolus reports robust Q4 earnings, eyes international expansion and profitability

Evolus' Q4 2022 performance exceeded expectations, driven by strong revenue growth and customer acquisition.
The company's strategic focus on market share gains, international expansion, and profitability sets a positive trajectory.
Challenges from new competition and market dynamics require strategic responses to maintain leadership.
Opportunities in international expansion, corporate development, and market growth position Evolus for future success.

Evolus secures strategic partnership for growth in dermal filler market

Evolus' strong Q1 performance and strategic partnership with Symatese position the company for significant growth in the dermal filler market.
While facing challenges in safety comparisons and patient demographics, Evolus has opportunities to leverage its unique manufacturing process and upcoming data releases for market advantage.
Overall, Evolus is well-funded, poised for profitability, and focused on differentiating its product line for long-term success.

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Evolus reports profitable Q2, eyes global expansion and new products

Evolus demonstrated strong performance in Q2 2024, achieving profitability and revenue growth.
The company's focus on innovation, international expansion, and financial management positions it for future success.
Challenges lie in maintaining growth momentum, executing expansion plans, and managing costs effectively.
Opportunities include capitalizing on market demand, global expansion, product innovation, and financial optimization.

Evolus reports strong Q3 growth, eyes $700M revenue target

Evolus showcased robust growth and strategic initiatives in Q3 2024, aiming for significant revenue targets by 2028. While facing revenue challenges and market competition, the company's strengths in product innovation and market expansion offer opportunities for sustained growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc. announces it has entered into a definitive agreement to be the exclusive U.S. distributor of a line of five unique dermal fillers.

Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc. announces that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023.

Evolus to Report First Quarter 2023 Results and Provide Business Update

Evolus: Capitalizing On The Growth Of Aesthetics Market

Evolus, Inc. (NASDAQ:EOLS ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants David Erickson - Vice President of Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Officer and Head of Research and Development Sandra Beaver - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Company, Inc. Marc Goodman - SVB Securities Douglas Tsao - H.C. Wainwright & Co. Louise Chen - Cantor Fitzgerald & Co. Navann Ty - BNP Paribas Exane Serge Belanger - Needham & Company, LLC Gregory Fraser - Truist Securities, Inc. Uy Ear - Mizuho Securities Co. Operator Greetings, and welcome to the Evolus Fourth Quarter 2022 Earnings Conference Call.

Evolus, Inc. (EOLS) Q4 2022 Earnings Call Transcript

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -14.29% and 0.39%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that members of its management team will be participating in the Barclays Global Healthcare Conference in Miami Beach, Florida.

Evolus to Participate in the Barclays Global Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus commences the commercial launch of Nuceiva® in Germany and Austria, and is now available for direct order and delivery to customers.

Evolus Initiates Nuceiva® Launch in Germany and Austria

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its fourth quarter and year end 2022 financial results and provide a business update on Wednesday, March 8, 2023.

Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus issues the following statement.

Evolus Not Affected by Recent Korean Court Ruling

Evolus' Jeuveau continues to see growth. Recent release of unaudited full-year 2022 financials showed revenues reaching $148.6 million, which was an increase of 49% over same period in 2021. It predicts that it will reach organic net revenue of $500 million by 2028.

Evolus: Extra Strength Dose Data Provides Additional Offering Expansion For Jeuveau

NEWPORT BEACH, Calif.--( BUSINESS WIRE )--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the SVB Securities Global Biopharma Conference.

Evolus to Participate in the SVB Securities Global Biopharma Conference

NEWPORT BEACH, Calif.--( BUSINESS WIRE )--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today presented interim data from its Phase II clinical study evaluating an "extra-strength" formulation for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product, at the 2023 International Master Course on Aging Science (IMCAS) World Congress in Paris. The data indicated that the “extra-strength” formulation of Jeuveau® at 40U (units) achieved a duration profile of 6 months or 26 weeks.

"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance

NEWPORT BEACH, Calif.--( BUSINESS WIRE )--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva® (prabotulinumtoxinA)▼, a neurotoxin dedicated exclusively to aesthetics. Nuceiva® was approved for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients. Glabellar lines are the vertical lines between the eyebrows seen at maximum frown.

Evolus Receives Regulatory Approval for Nuceiva® in Australia

NEWPORT BEACH, Calif.--( BUSINESS WIRE )--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, will present interim findings from a Phase 2 study evaluating the safety, efficacy and duration of effect for its “extra-strength” dose of Jeuveau® (prabotulinumtoxinA-xvfs) – the company's flagship neurotoxin product – at the 2023 International Master Course on Aging Science (IMCAS) World Congress on January 28, 2023 in Paris.

Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress

The company said it expects to turn a profit in the fourth quarter.

Why Evolus Shares Jumped This Week

NEWPORT BEACH, Calif.--( BUSINESS WIRE )--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its preliminary, unaudited net revenue as of and for the fourth quarter and full-year ended December 31, 2022. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company's 2022 financial results is completed and the company reports its full financial results for the fourth quarter and full-year 2022, which is anticipated to occur in early March 2023.

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration

NEWPORT BEACH, Calif.--( BUSINESS WIRE )--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it has extended the expiration date of the second undrawn tranche under its existing term loan financing facility with investment funds managed by Pharmakon Advisors, LP to December 31, 2023.

Evolus Extends Term of Credit Facility with Pharmakon Advisors

NEW BRUNSWICK, N.J. , Dec. 7, 2022 /PRNewswire/ -- Pipeline Medical, a MedTech marketplace focused on supplying pharmaceuticals and medical supplies to medical professionals around the country, recently announced the addition of Jeuveau® (prabotulinumtoxinA-xvfs) by Evolus, Inc. (NASDAQ: EOLS).

Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc.

Evolus, Inc. (NASDAQ:EOLS ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Erickson – Vice President-Investor Relations David Moatazedi – President and Chief Executive Officer Sandra Beaver – Chief Financial Officer Conference Call Participants Marc Goodman – SVB Securities Carvey Leung – Cantor Fitzgerald Annabel Samimy – Stifel Douglas Tsao – H.C. Wainwright Operator Greetings, and welcome to the Evolus Third Quarter 2022 Earnings Conference Call.

Evolus, Inc. (EOLS) Q3 2022 Earnings Call Transcript

Evolus Reports Third Quarter 2022 Results and Provides Business Update

Evolus to Participate in November Conferences

Evolus to Report Third Quarter 2022 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc., launched commercial operations in Great Britain and shipped the first customer orders for Nuceiva®▼(botulinum toxin type A) last month.

Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus celebrates the conclusion of certain royalty payments that resulted from the 2021 settlement of litigation claims.

News for Evolus Stock (EOLS)